Product Details
| Product Name:
Sabizabulin |
CAS No.:
1332881-26-1 |
| Purity:
98.50% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | Sabizabulin |
| Description | Sabizabulin (ABI-231) is a potent, orally bioavailable α- and β-tubulin inhibitor that is active against melanoma and prostate cancer cell lines. Sabizabulin inhibits tumor growth and metastatic phenotypes of cervical cancer cells by targeting HPV E6 and E7 and is also being studied in prostate cancer. |
| In vitro | METHODS: BT474 and SKBR3 cells were treated with Sabizabulin (ABI-231) (4, 8, 12, 16 nM), and cell growth inhibition was measured by MTS assay.
RESULTS Sabizabulin (ABI-231) significantly inhibited the growth of BT474 and SKBR3 cells in a concentration-dependent manner with IC50 values ??of 9.07 and 8.18 nM, respectively, and had low cytotoxicity. [1] |
| In vivo | METHODS: Sabizabulin (ABI-231) (17 mg/kg/20 mg/kg, oral, three weeks) was used to treat BT474 xenograft/HCI-12 PDX model mice and its therapeutic effect was observed.
RESULTS Sabizabulin (ABI-231) significantly reduced the tumor volume and tumor wet weight of terminal BT474 xenograft mice, inhibited tumor growth and suppressed lung metastasis in HCI-12 PDX model mice. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (132.49 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.3 mM), Sonication is recommended.
|
| Keywords | VERU111 | VERU 111 | tubulin | Sabizabulin | MicrotubuleAssociated | Microtubule Associated | ABI231 | ABI 231 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Thymidine | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States